



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/60

August 18, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. “**Biocon Announces U.S. FDA Approval for Yesintek® (ustekinumab-kfce) Single-dose Prefilled Autoinjector**”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Announces U.S. FDA Approval for Yesintek® (ustekinumab-kfce) Single-dose Prefilled Autoinjector

Bengaluru, Karnataka, India, August 18, 2026

Biocon Limited's subsidiary in the United States has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek® 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek® 90 mg/ml single-dose prefilled autoinjector. Yesintek® was originally approved by the U.S. FDA on November 29, 2024.

The Yesintek® single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.

Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn's disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.

This supplemental approval enhances Biocon's comprehensive portfolio of immunology products in the United States and reaffirms the company's commitment to improving access to affordable medicines for patients around the world.

– Company Spokesperson